Skip to main content
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock () or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Table 2f. Characteristics of Antiviral Agents

Last Updated: May 31, 2022

  • RDV is the only antiviral drug that is approved by the FDA for the treatment of COVID-19.
  • RTV-boosted nirmatrelvir, MOV, and certain anti-SARS-CoV-2 mAbs have received EUAs from the FDA for the treatment of COVID-19.
  • Other medications that are currently being evaluated in clinical trials for the treatment of COVID-19 are also included in this table. The inclusion of these drugs does not imply that the Panel recommends their use.
  • This table focuses on small-molecule antiviral drugs. For more information regarding anti-SARS-CoV-2 mAbs, please see Table 3c.
  • Information on CQ, HCQ, and LPV/RTV are available in archived versions of the Guidelines. The Panel recommends against using these agents to treat COVID-19.
  • For many of these antiviral drugs, there are limited or no data on dose modifications for patients with organ failure or those who require extracorporeal devices. Please refer to product labels or EUAs, when available.
  • For drug interaction information, please refer to product labels, EUA fact sheets, and the Liverpool COVID-19 Drug Interactions website.
  • For the Panel’s recommendations on using the drugs listed in this table, please refer to the individual drug sections, Therapeutic Management of Nonhospitalized Adults With COVID-19, Therapeutic Management of Hospitalized Adults With COVID-19, or Antiviral Therapy Summary Recommendations.
Table 2f. Characteristics of Antiviral Agents
Table 2f. Characteristics of Antiviral Agents

References

  1. Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for Paxlovid. 2022. Available at: https://www.fda.gov/media/155050/download.
  2. Remdesivir (Veklury) [package insert]. Food and Drug Administration. 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214787Orig1s000lbl.pdf.
  3. Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for molnupiravir. 2022. Available at: https://www.fda.gov/media/155054/download.
  4. Ivermectin (Stromectol) [package insert]. Food and Drug Administration. 2009. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050742s024s025lbl.pdf.
  5. Nitazoxanide (Alinia) [package insert]. Food and Drug Administration. 2016. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021497s001,021498s004lbl.pdf.